{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:18:32Z","timestamp":1792693112400,"version":"4.5.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>For patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) with a progressive pulmonary fibrosis (PPF) phenotype, current knowledge of patient experience and symptom burden is limited. This study aimed to describe the patient journey for patients with PPF and IPF in a real-world setting in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were analyzed from the Adelphi Real World PPF-ILD Disease Specific Programme\u2122, a cross-sectional survey with elements of retrospective data collection of pulmonologists and rheumatologists in Japan from April to October 2022. Participants provided data for up to 12 consecutive patients with physician-confirmed ILD with a progressive phenotype. Analyses were descriptive, except Kappa (\u03ba) statistic was used to measure the alignment between physician- and patient-reported symptom burden in the 4 weeks prior to survey date (poor agreement: \u03ba =&amp;lt;0.00; slight 0.00\u20130.20; fair 0.21\u20130.40; moderate 0.41\u20130.60; substantial 0.61\u20130.80; almost perfect 1.00).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 63 physicians (43 pulmonologists and 20 rheumatologists) provided data on 382 patients (312 with PPF and 70 with IPF). These patients were also asked to complete a voluntary survey on their experience and symptoms. Mean time from first symptom to consultation was 14.1 months for IPF, 8.0 months for non-connective tissue disease (CTD)-associated ILDs, and 10.7 months for CTD-ILDs. Mean times from consultation to diagnosis were 7.1, 4.8, and 3.6 months, respectively. Perception of symptoms differed between physicians and patients with alignment ranging from poor (dysphagia, \u03ba = \u20130.0296, <jats:italic>p<\/jats:italic> = 0.6217) to substantial (weight loss, \u03ba = 0.6174, <jats:italic>p<\/jats:italic> = 0.001). Health-related quality of life (HRQoL) was consistently impaired in patients overall, but too few patients completed HRQoL instruments to compare IPF with other forms of ILD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This real-world study expands our understanding of the patient journey for patients with PPF and IPF in Japan. Greater communication between patients and physicians is needed to shorten diagnostic delays and target treatment strategies to improve patient experience and overall outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1526530","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:43:21Z","timestamp":1744375401000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The patient journey and burden of disease in progressive pulmonary fibrosis in Japan: a cross-sectional survey"],"prefix":"10.3389","volume":"12","author":[{"given":"Yuko","family":"Kaneko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Waseda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekata","family":"Yasuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masateru","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruyuki","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an Update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline.","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"00170","DOI":"10.1183\/23120541.00170-2018","article-title":"Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.","volume":"5","author":"Kaunisto","year":"2019","journal-title":"ERJ Open Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s12325-018-0693-1","article-title":"Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK.","volume":"35","author":"Strongman","year":"2018","journal-title":"Adv Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"180100","DOI":"10.1183\/16000617.0100-2018","article-title":"Fibrosing interstitial lung diseases: Knowns and unknowns.","volume":"28","author":"Cottin","year":"2019","journal-title":"Eur Respir Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases.","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2019.06.001","article-title":"Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015.","volume":"155","author":"Sk\u00f6ld","year":"2019","journal-title":"Respir Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"711194","DOI":"10.3389\/fmed.2021.711194","article-title":"Patient reported experiences and delays during the diagnostic pathway for pulmonary fibrosis: A multinational european survey.","volume":"8","author":"van der Sar","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"B8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/resp.14154","article-title":"Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden.","volume":"27","author":"Lancaster","year":"2022","journal-title":"Respirology."},{"key":"B9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1183\/13993003.congress-2020.768","article-title":"Idiopathic pulmonary fibrosis (IPF): The patient journey.","volume":"56","author":"Cottin","year":"2020","journal-title":"Eur Respiratory Soc."},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12890-021-01431-8","article-title":"Patients\u2019 and healthcare professionals\u2019 perspectives on the idiopathic pulmonary fibrosis care journey: A qualitative study.","volume":"21","author":"Delameillieure","year":"2021","journal-title":"BMC Pulm Med"},{"key":"B11","first-page":"A1678","article-title":"Non-IPF progressive fibrosing interstitial lung disease (PF-ILD): The patient journey.","volume":"197","author":"Wijsenbeek","year":"2018","journal-title":"Am J Respiratory Crit Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1106560","DOI":"10.3389\/fmed.2023.1106560","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: A cohort study.","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)."},{"key":"B13","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.1007\/s10238-023-01212-z","article-title":"Clinical effect of progressive pulmonary fibrosis on patients with connective tissue disease-associated interstitial lung disease: A single center retrospective cohort study.","volume":"23","author":"Lee","year":"2023","journal-title":"Clin Exp Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: disease-specific programmes - A means to understand.","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin."},{"key":"B15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: A long-term view of real-world treatment between 2000 and 2015.","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1080\/03007995.2023.2279679","article-title":"Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: An update on disease specific programmes.","volume":"39","author":"Anderson","year":"2023","journal-title":"Curr Med Res Opin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1526531","DOI":"10.3389\/fmed.2024.1526531","article-title":"Treatment patterns and clinical profile in progressive pulmonary fibrosis: a Japanese cross-sectional survey.","volume":"11","author":"Yasuoka","year":"2025","journal-title":"Front Med (Lausanne)."},{"key":"B18","author":"Reilly","year":"","journal-title":"WPAI:SHP V2.0 2010."},{"key":"B19","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/thoraxjnl-2012-201581","article-title":"The development and validation of the King\u2019s brief interstitial lung disease (K-BILD) health status questionnaire.","volume":"67","author":"Patel","year":"2012","journal-title":"Thorax."},{"key":"B21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12955-015-0214-8","article-title":"Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference.","volume":"13","author":"D\u00fcr","year":"2015","journal-title":"Health Qual Life Outcomes."},{"key":"B22","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/art.22605","article-title":"Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning.","volume":"57","author":"Stamm","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e29998","DOI":"10.1097\/MD.0000000000029998","article-title":"Association between chronic pain with presarcopenia and central sensitization in Japanese community-dwelling older adults: A cross-sectional study.","volume":"101","author":"Imai","year":"2022","journal-title":"Medicine (Baltimore)."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1526530\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T12:43:23Z","timestamp":1744375403000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1526530\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":23,"alternative-id":["10.3389\/fmed.2025.1526530"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1526530","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"article-number":"1526530"}}